Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12239007 | 0.93 | CRBN (0.38) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL12302393 | 0.93 | ACACB (0.33) | CYP3A4CYP2C9CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL12238775 | 0.91 | VNN1 (0.35) | — | |
| SCHEMBL12239806 | 0.90 | CHRM2 (0.41) | CYP3A4CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL1684651 | 0.90 | CYP2D6 (0.40) | CYP3A4CYP2C9CYP2C19HSD17B10CYP2D6 | |
| SCHEMBL12239804 | 0.89 | ACACB (0.37) | CYP3A4CYP2C9HSD17B10CYP2D6CYP1A2 | |
| SCHEMBL12302535 | 0.89 | CYP3A4 (0.43) | CYP3A4CYP2C9HSD17B10CYP2D6CYP1A2 | |
| SCHEMBL12239196 | 0.88 | CCR8 (0.36) | CYP3A4CYP2C9HSD17B10CYP1A2USP2 | |
| SCHEMBL12239195 | 0.87 | ACACB (0.35) | CYP3A4CYP2D6CYP1A2MEN1KMT2A | |
| SCHEMBL2143530 | 0.85 | HSD17B10 (0.37) | CYP3A4CYP2C9CYP2C19HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | SCNN1B, SCNN1A, SCNN1G | CYP3A4 3246/4885CYP2C9 2108/4885CYP2C19 2528/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | CYP3A4 988/4885CYP2C9 335/4885CYP2C19 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.